Application of immune checkpoint inhibitors in the treatment of small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 747-750, 2021.
Article
em Zh
| WPRIM
| ID: wpr-930033
Biblioteca responsável:
WPRO
ABSTRACT
The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Ano de publicação:
2021
Tipo de documento:
Article